Relmada Therapeutics Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Relmada Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $12.8. The average 1-year stock price forecast is 92.48% higher than the current stock price, while the lowest is $9.00 (+35.34%) and the highest is $19 (+185.71%).

Price Target: $12.8 (+92.48%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$9.00	$12.8	$12	$19
Change	+35.34%	+92.48%	+80.45%	+185.71%

* Price targets were last updated on May 13, 2026.

Analyst Ratings

The average analyst rating for Relmada Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	2	3	3	4	4	4
Buy	0	0	0	1	1	1
Hold	1	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	5	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Kelsey Goodwin Piper Sandler	Piper Sandler	Buy Maintains $12	Buy	Maintains	$12	+80.45%	May 13, 2026
Uy Ear Mizuho Securities	Mizuho Securities	Buy Reiterates $19	Buy	Reiterates	$19	+185.71%	May 13, 2026
Christopher Liu Lucid Capital	Lucid Capital	Buy Initiates $14	Buy	Initiates	$14	+110.53%	Mar 2, 2026
Andrew Berens Leerink Partners	Leerink Partners	Buy Initiates $8	Buy	Initiates	$8	+20.30%	Jan 23, 2026
Farzin Haque Jefferies	Jefferies	Buy Initiates $9	Buy	Initiates	$9	+35.34%	Dec 22, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.48

from -1.10

EPS Next Year

-0.48

from -0.48

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-125.70M	-161.25M	-103.70M	-83.89M	-56.20M	-84.37M
Net Income	-125.75M	-157.04M	-98.79M	-79.98M	-57.39M	-81.81M
EPS	-	-	-	-	-1.10	-0.48
Free Cash Flow	-46.02M	-52.34M	-17.91M	-23.85M	-23.21M	-30.00M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.48
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-